Biomaterial Database

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark. 2024

Katrine Finderup Nielsen, and Lise Birk Nielsen, and Tine Dalby, and Frederikke Kristensen Lomholt, and Hans-Christian Slotved, and Kurt Fuursted, and Zitta Barrella Harboe, and Charlotte Sværke Jørgensen, and Palle Valentiner-Branth

As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020-January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D011008	Pneumococcal Infections	Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D003718	Denmark	A country in northern Europe, bordering the Baltic Sea and the North Sea. The capital is Copenhagen.	Faeroe Islands,Faroe Islands
D005260	Female		Females
D005500	Follow-Up Studies	Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.	Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000087507	Vaccine Efficacy	A measurement of disease risk reduction among vaccinated compared to unvaccinated persons under ideal conditions such as in a clinical trial. Such disease reduction measured under typical field conditions is vaccine effectiveness. In contrast vaccine potency is measured in an assay to ensure proper dosing and storage of vaccines whereas vaccine immunogenicity measures its ability to induce an immune response in a vaccinated individual in observational studies.	Vaccine Effectiveness,Efficacy, Vaccine
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D000369	Aged, 80 and over	Persons 80 years of age and older.	Oldest Old
D013296	Streptococcus pneumoniae	A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals.	Diplococcus pneumoniae,Pneumococcus